STAA · Staar Surgical Co · Insider Trading

Represents the settlement of the third tranche of PSUs awarded to the Reporting Person in connection with her new hire grant under the 2025 PSU Program. The number of shares earned was determined upon certification by the Compensation Committee based on achievement of applicable performance goals. The original grant was exempt pursuant to Rule 16b-3(d) and was not previously reported.

The Reporting Person was granted an option to purchase 40,471 shares of Company common stock. The shares underlying the option vest over three years from the Grant Date, with one-third vesting on the first anniversary of the Grant Date and the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter

The Reporting Person was granted a performance option to purchase 131,830 shares of Company common stock. The shares underlying the option vest over a performance period ending on the earlier of a change in control and the 10-year anniversary of the Grant Date, subject to achievement of stock-price hurdles of $50.00, $75.00 and $100.00 per share, and time vest as to one-third on the first anniversary of the Grant Date with the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter.

Represents the settlement of the third tranche of 5,499 PSUs awarded to the Reporting Person under the Issuer's 2025 PSU Program in connection with her annual equity grant vested. The number of shares earned was determined upon certification by the Compensation Committee based on achievement of applicable performance goals. The original grant was exempt pursuant to Rule 16b-3(d) and was not previously reported.

The Reporting Person was granted an option to purchase 37,962 shares of Company common stock. The shares underlying the option vest over 42 months from the Grant Date, with one-third vesting on the 18-month anniversary of the Grant Date and the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter.

Each restricted stock unit ("RSU") represents the right to receive one share of STAAR Surgical Company ("Company") common stock upon vesting.

The Reporting Person was granted Company RSUs on August 14, 2026 (the "Grant Date"). These RSUs vest as to one-third on the first anniversary of the Grant Date, and the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter.

The Reporting Person was granted Issuer restricted stock units (RSUs) on August 14, 2026 (the "Grant Date"). These RSUs vest as to one-third on the first anniversary of the Grant Date, and the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter.

On August 14, 2026, the third tranche of 3,666 PSUs awarded to the Reporting Person under the Issuer's 2025 PSU Program in connection with his expanded role as President and Chief Operating Officer vested, of which 1,865 shares were withheld to satisfy taxes.

The Reporting Person was granted a performance option to purchase 29,159 shares of Company common stock. The shares underlying the option vest over a performance period ending on the earlier of a change in control and the 10-year anniversary of the Grant Date, subject to achievement of stock-price hurdles of $50.00, $75.00 and $100.00 per share, and time vest as to one-third on the anniversary of the Grant Date with the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter.

Each RSU represents the right to receive one share of the Corporation's common stock upon vesting.

The Reporting Person was granted Issuer restricted stock units (RSUs) on August 14, 2026 (the "Grant Date"). These RSUs vest as to 1/3 on the first anniversary of the Grant Date, and the remaining 2/3 vesting in 24 substantially equal monthly installments thereafter.

The Reporting Person was granted an option to purchase 8,952 shares of Company common stock. The shares underlying the option vest over three years from the Grant Date, with one-third vesting on the first anniversary of the Grant Date and the remaining two-thirds vesting in 24 substantially equal monthly installment thereafter.

Due to clerical errors, the Reporting Person's prior Form-4 filed with the Securities and Exchange Commission on May 12, 2026 incorrectly reported this value as 32,691 shares when the Reporting Person beneficially owned 28,008 shares and the Reporting Person's prior Form 4 filed with the SEC on May 19, 2026 incorrectly reported this value as 46,026 when the Reporting Person beneficially owned 38.100. The values have been corrected herein.

On May 15, 2026, the third tranche of 5,233 performance stock units ("PSUs") awarded to the Reporting Person under the 2025 PSU Program in connection with her new hire grant vested, of which 2,662 shares were withheld to satisfy taxes.

Represents the settlement of the third tranche of PSUs awarded under the 2025 PSU Program to the Reporting Person in connection with his expanded role as President & Chief Operating Officer. The number of shares earned was determined upon certification by the Compensation Committee based on achievement of applicable performance goals. The original grant was exempt pursuant to Rule 16b-3(d) and was not previously reported.

On August 14, 2026, the third tranche of 5,499 performance stock units ("PSUs") awarded to the Reporting Person under the Issuer's 2025 Performance Stock Award Program ("2025 PSU Program") in connection with her annual equity grant vested, of which 2,797 shares were withheld to satisfy taxes.

On August 14, 2026, the third tranche of 7,331 performance stock units ("PSUs") awarded to the Reporting Person under the Issuer's 2025 Performance Stock Award Program ("2025 PSU Program") in connection with his annual equity grant vested, of which 3,730 shares were withheld to satisfy taxes.

The Reporting Person was granted a performance option to purchase 123,659 shares of Company common stock. The shares underlying the option vest over a performance period ending on the earlier of a change in control and the 10-year anniversary of the Grant Date, subject to achievement of stock-price hurdles of $50.00, $75.00 and $100.00 per share, and time vest as to one-third on the 18-month anniversary of the Grant Date with the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter.

Represents the settlement of the third tranche of of 1,100 PSUs awarded to the Reporting Person under the Issuer's 2025 PSU Program in connection with her promotion to Chief Development Officer vested. The number of shares earned was determined upon certification by the Compensation Committee based on achievement of applicable performance goals. The original grant was exempt pursuant to Rule 16b-3(d) and was not previously reported.

Represents the settlement of the third tranche of PSUs awarded to the Reporting Person in connection with his annual equity grant under the 2025 PSU Program. The number of shares was determined upon certification by the Compensation Committee based on achievement of applicable performance goals. The original grant was exempt pursuant to Rule 16b-3(d) and was not previously reported.

Represents the vesting of restricted stock units ("RSUs") granted to the Reporting Person on February 2, 2026, in connection with his appointment as Interim Co-Chief Executive Officer of the Issuer on such date. These RSUs vested on July 31, 2026. The RSUs convert into common stock on a one-for-one basis.

Represents the vesting of restricted stock units ("RSUs") granted to the Reporting Person on February 2, 2026, in connection with his appointment as Interim Co-Chief Executive Officer of the Issuer on such date. These RSUs vested on July 31, 2026. The RSUs convert into common stock on a one-for-one basis.

Due to clerical errors, the Reporting Person's prior Form 4 filed with the Securities and Exchange Commission on May 19, 2026, incorrectly reported this value as 83,112 when the Reporting Person beneficially owned 76,345 shares. The values have been corrected herein.

Represents the vesting of RSUs granted to the Reporting Person on February 2, 2026, in connection with the Reporting Person's appointment as Interim Co-Chief Executive Officer of the Issuer on such date. The RSUs vested on July 31, 2026. The RSUs convert into common stock on a one-for-one basis.

Represents the vesting of RSUs granted to the Reporting Person on February 2, 2026, in connection with the Reporting Person's appointment as Interim Co-Chief Executive Officer of the Issuer on such date. The RSUs vested on July 31, 2026. The RSUs convert into common stock on a one-for-one basis.

Represents the vesting of restricted stock units ("RSUs") granted to the Reporting Person on June 25, 2025, in connection with her appointment as Chief Financial Officer of the Issuer on such date. These RSUs vest as to 1/3 of the shares subject to the award on each of June 25, 2026, 2027 and 2028. The RSUs convert into common stock on a one-for-one basis.

Represents the vesting of restricted stock units ("RSUs") granted to the Reporting Person on June 25, 2025, in connection with her appointment as Chief Financial Officer of the Issuer on such date. These RSUs vest as to 1/3 of the shares subject to the award on each of June 25, 2026, 2027 and 2028. The RSUs convert into common stock on a one-for-one basis.

Reflects restricted stock units and options to purchase common stock granted to the Reporting Person on June 18, 2026, pursuant to the Issuer's annual non-employee director equity compensation program for the 2026-2027 term. These equity awards vest in full on the earlier of June 18, 2027 or the Issuer's 2027 Annual Meeting of Shareholders.

Reflects restricted stock units granted to the Reporting Person on June 18, 2025, pursuant to the Issuer's annual non-employee director equity compensation program for the 2025-2026 term, which vested on June 18, 2026.

These options were granted to the Reporting Person by the Issuer on June 18, 2026 as director compensation pursuant to the Issuer's Amended and Restated Omnibus Equity Incentive Plan, as amended.

These options will vest and become exercisable on the earlier of: (a) June 18, 2027 and (b) the date of STAAR Surgical Company's (the "Issuer") next annual meeting of shareholders after the grant date, subject, in each case, to Richard T. LeBuhn's (the "Reporting Person") continuous service with the Issuer.

Award of stock options granted to the Reporting Person on June 18, 2026. These stock options will vest in full on the earlier of June 18, 2027 or the Issuer's 2026 annual meeting of shareholders.

Reflects restricted stock units and options to purchase common stock granted to the Reporting Person on June 18, 2026, pursuant to the Issuer's annual non-employee director equity compensation program for the 2026-2027 term. These equity awards vest in full on the earlier of June 18, 2027 or the Issuer's 2027 Annual Meeting of Shareholders.

Reflects restricted stock units and options to purchase common stock granted to the Reporting Person on June 18, 2026, pursuant to the Issuer's annual non-employee director equity compensation program for the 2026-2027 term. These equity awards vest in full on the earlier of June 18, 2027 or the Issuer's 2027 Annual Meeting of Shareholders.

Reflects restricted stock units granted to the Reporting Person on June 18, 2025, pursuant to the Issuer's annual non-employee director equity compensation program for the 2025-2026 term, which vested on June 18, 2026.

Reflects restricted stock units granted to the Reporting Person on June 18, 2026, pursuant to the Issuer's annual non-employee director equity compensation program for the 2026-2027 term. These equity awards vest in full on the earlier of June 18, 2027 or the Issuer's 2027 Annual Meeting of Shareholders.

Reflects restricted stock units granted to the Reporting Person on June 18, 2025, pursuant to the Issuer's annual non-employee director equity compensation program for the 2025-2026 term, which vested on June 18, 2026.

These options were granted to the Reporting Person by the Issuer on June 18, 2026 as director compensation pursuant to the Issuer's Amended and Restated Omnibus Equity Incentive Plan, as amended.

These options will vest and become exercisable on the earlier of: (a) June 18, 2027 and (b) the date of STAAR Surgical Company's (the "Issuer") next annual meeting of shareholders after the grant date, subject, in each case, to Neal C. Bradsher's (the "Reporting Person") continuous service with the Issuer.

Reflects restricted stock units granted to the Reporting Person on June 18, 2026, pursuant to the Issuer's annual non-employee director equity compensation program for the 2026-2027 term. These equity awards vest in full on the earlier of June 18, 2027 or the Issuer's 2027 Annual Meeting of Shareholders.

Reflects restricted stock units granted to the Reporting Person on June 18, 2025, pursuant to the Issuer's annual non-employee director equity compensation program for the 2025-2026 term, which vested on June 18, 2026.

Reflects restricted stock units granted to the Reporting Person on June 18, 2025, pursuant to the Issuer's annual non-employee director equity compensation program for the 2025-2026 term, which vested on June 18, 2026.

Reflects restricted stock units granted to the Reporting Person on June 18, 2025, pursuant to the Issuer's annual non-employee director equity compensation program for the 2025-2026 term, which vested on June 18, 2026.

Reflects restricted stock units and options to purchase common stock granted to the Reporting Person on June 18, 2026, pursuant to the Issuer's annual non-employee director equity compensation program for the 2026-2027 term. These equity awards vest in full on the earlier of June 18, 2027 or the Issuer's 2027 Annual Meeting of Shareholders.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $28.215 to $28.35, inclusive.

Represents the settlement of the first tranche of performance stock units awarded to the Reporting Person in connection with her new hire grant under the 2025 PSU Program. The number of shares earned was determined upon certification by the Compensation Committee based on achievement of applicable performance goals. The original grant was exempt pursuant to Rule 16b-3(d) and was not previously reported.